Free Trial
NASDAQ:MDGL

Madrigal Pharmaceuticals Q2 2025 Earnings Report

Madrigal Pharmaceuticals logo
$319.74 +4.28 (+1.36%)
Closing price 03:59 PM Eastern
Extended Trading
$319.50 -0.24 (-0.08%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Madrigal Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$3.64
Beat/Miss
N/A
One Year Ago EPS
N/A

Madrigal Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$158.94 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Madrigal Pharmaceuticals Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
8:00AM ET

Conference Call Resources

Madrigal Pharmaceuticals Earnings Headlines

This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
See More Madrigal Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Madrigal Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Madrigal Pharmaceuticals and other key companies, straight to your email.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals (NASDAQ:MDGL) (NASDAQ: MDGL) is a clinical-stage biopharmaceutical company focused on the development of targeted therapies for non-alcoholic steatohepatitis (NASH) and other metabolic liver diseases. The company’s lead product candidate, resmetirom (MGL-3196), is an oral, selective thyroid hormone receptor-β agonist designed to reduce liver fat and improve markers of inflammation and fibrosis in patients with NASH. Madrigal is also exploring additional compounds aimed at treating dyslipidemia and cardiovascular risk factors associated with metabolic liver disease.

Since its founding in 2012 and incorporation in Delaware, Madrigal has pursued a strategy of advancing novel, mechanism-based therapies from early discovery through clinical development. The company’s research programs leverage insights into thyroid hormone receptor biology to address underlying drivers of liver injury. Resmetirom has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration, reflecting the unmet medical need in NASH and the promising clinical data observed to date.

Madrigal Pharmaceuticals maintains its headquarters in Conshohocken, Pennsylvania, and operates a lean, clinical-focused organization that partners with contract research organizations and academic investigators across North America and Europe. The company’s global approach to clinical trials seeks to enroll a diverse patient population, with ongoing Phase 3 studies evaluating resmetirom’s efficacy and safety in reducing liver fat and improving histological outcomes.

Under the leadership of President and Chief Executive Officer James E. Sapirstein, who joined Madrigal in 2021, the company has strengthened its management team to support late-stage development and regulatory interactions. With a seasoned board of directors and scientific advisory board composed of experts in hepatology and endocrinology, Madrigal remains committed to delivering transformative therapies for patients suffering from metabolic liver diseases.

View Madrigal Pharmaceuticals Profile

More Earnings Resources from MarketBeat